SCHEMBL30294352

SCHEMBL30294352

COc1cc(F)ccc1Nc1ccc(Cl)cc1C(=O)O

nearest known ligand 0.61

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KDM4E B2RXH2 3/20 0.54
GAA P10253 1/20 0.54
APAF1 O14727 1/20 0.53
RECQL P46063 1/20 0.53
CASP6 P55212 1/20 0.53
CACNA1B Q00975 1/20 0.53
APBA1 Q02410 1/20 0.53
MCL1 Q07820 1/20 0.53
CASP8 Q14790 1/20 0.53
AKR1C3 P42330 1/20 0.53
AKR1C2 P52895 1/20 0.53
KMT2A Q03164 3/20 0.52
MEN1 O00255 2/20 0.52
LMNA P02545 2/20 0.52
MAPT P10636 2/20 0.52
POLB P06746 1/20 0.52
DHODH Q02127 1/20 0.50
HSD17B10 Q99714 1/20 0.50
HPGD P15428 1/20 0.50
GFER P55789 1/20 0.50

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL22852839 1.00 KDM4E (0.54) KDM4EGAAAPAF1RECQLCASP6
SCHEMBL30294853 0.90 KMT2A (0.51) KDM4EAPAF1RECQLCASP6CACNA1B
SCHEMBL22853031 0.90 KMT2A (0.51) KDM4EAPAF1RECQLCASP6CACNA1B
SCHEMBL22853109 0.86 MRGPRX1 (0.56) KDM4EGAAKMT2AMEN1LMNA
SCHEMBL30294316 0.86 MRGPRX1 (0.56) KDM4EGAAKMT2AMEN1LMNA
SCHEMBL22853477 0.85 KCNMA1 (0.56) KDM4EGAAAPAF1RECQLCASP6
SCHEMBL30294462 0.85 KCNMA1 (0.56) KDM4EGAAAPAF1RECQLCASP6
SCHEMBL30294465 0.85 KCNMA1 (0.56) KDM4EGAAAPAF1RECQLCASP6
SCHEMBL22853479 0.84 KDM4E (0.52) KDM4EAPAF1RECQLCASP6CACNA1B
SCHEMBL30294307 0.84 KDM4E (0.52) KDM4EAPAF1RECQLCASP6CACNA1B

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20230103791-A1 2,3-DIHYDROQUINAZOLIN COMPOUNDS AS NAV1.8 INHIBITORS GLAXOSMITHKLINE INTELLECTUAL PROPERTY DEVELOPMENT LIMITED (GB) 2023-04-06 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230103791-A1 2,3-DIHYDROQUINAZOLIN COMPOUNDS AS NAV1.8 INHIBITORS SCN8A, SCN1A, SCN1B KDM4E 3392/4885GAA 2380/4885APAF1 3972/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.